Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

China flag China · Delayed Price · Currency is CNY
38.81
-0.58 (-1.47%)
Jul 3, 2026, 3:00 PM CST
Market Cap9.42B +181.3%
Revenue (ttm)1.56B +12.8%
Net Income112.17M +51.6%
EPS0.50 +47.6%
Shares Out 242.81M
PE Ratio77.63
Forward PEn/a
Dividend0.16 (0.40%)
Ex-Dividend DateJun 25, 2025
Volume73,976,592
Open42.69
Previous Close39.39
Day's Range37.21 - 42.70
52-Week Range18.97 - 70.39
Beta-0.05
Analystsn/a
Price Targetn/a
Earnings DateAug 12, 2026

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China. [Read more]

Sector Healthcare
Founded 2004
Employees 2,370
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603538
Full Company Profile

Financial Performance

In 2025, SHA:603538's revenue was 1.50 billion, an increase of 9.49% compared to the previous year's 1.37 billion. Earnings were 102.23 million, an increase of 53.02%.

Financial Statements